

July, 2007

Evolva and Summit sign collaboration to develop anti-infectives

Evolva SA and Summit have entered into a collaboration for co-development of immuno-modulators for the treatment and prevention of certain infectious diseases. The aim of the collaboration is to bring one or more compounds to the IND stage, at which point the two parties will decide the further development.

The joint venture combines Summit's expertise in carbohydrate chemistry, including existing compounds, with Evolva's ongoing activities in identification and development of new anti-infectives.

About Evolva SA. Evolva develops small molecule drugs based upon proprietary genetic chemistry technologies. Founded in 2004, it currently has pre-clinical stage compounds in the anti-infective and cardiovascular/metabolic disease space, and third party discovery collaborations in cancer, antiviral and immuno-modulators. Evolva employs c. 70 people in Switzerland, India and Denmark. For more information see www.evolva.com (<http://www.evolva.com>).

About Summit plc. Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

Further information about the company is available at www.summitplc.com (<http://www.summitplc.com/>).



Tel: +41 61 485 2000
Fax: +41 61 485 2001

General Enquiries:
info@evolva.com

Business Enquiries:
busdev@evolva.com

www.evolva.com